Mar 08, 2023 Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
Mar 02, 2023 Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
Jan 31, 2023 Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
Jan 27, 2023 Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Nov 10, 2022 Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 08, 2022 Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Sep 22, 2022 Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
